14-day Premium Trial Subscription Try For FreeTry Free
Good morning, everyone, and thank you for joining us on our first-quarter 2020 financial results and business update conference call. This morning, before the open, we issued a press release providin
Q1 2020 Ocular Therapeutix Inc Earnings Call

Ocular Therapeutix: Q1 Earnings Insights

12:43pm, Friday, 08'th May 2020
Shares of Ocular Therapeutix (NASDAQ:OCUL) were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 8.89% year over year to ($0.41), whic
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) • Acceleron Pharma Inc (...
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Ocular Therapeutix (NASDAQ:OCUL) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, BidA

BBBY, DVAX among premarket gainers

01:22pm, Tuesday, 28'th Apr 2020
Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avast
Gainers Document Security Systems, Inc. (NYSE: DSS) shares rose 43.8% to $0.43 in pre-market trading after the company reported completion of required independent valuation,...
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Wall Street analysts predict that Ocular Therapeutix Inc (NASDAQ:OCUL) will announce earnings per share of ($0.40) for the current fiscal quarter, according to Zacks. Four analysts have provided estim
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE